121 related articles for article (PubMed ID: 38170737)
21. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
Akslen LA; Puntervoll H; Bachmann IM; Straume O; Vuhahula E; Kumar R; Molven A
Melanoma Res; 2008 Feb; 18(1):29-35. PubMed ID: 18227705
[TBL] [Abstract][Full Text] [Related]
22. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
23. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
24. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
25. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
26. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
[TBL] [Abstract][Full Text] [Related]
27. BRAF V600 mutations and pathological features in Japanese melanoma patients.
Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K
Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
29. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
Dika E; Veronesi G; Altimari A; Riefolo M; Ravaioli GM; Piraccini BM; Lambertini M; Campione E; Gruppioni E; Fiorentino M; Melotti B; Ferracin M; Patrizi A
Am J Clin Pathol; 2020 Apr; 153(5):664-671. PubMed ID: 32017841
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
[TBL] [Abstract][Full Text] [Related]
31. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
32. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
Zimmer L; Hillen U; Livingstone E; Lacouture ME; Busam K; Carvajal RD; Egberts F; Hauschild A; Kashani-Sabet M; Goldinger SM; Dummer R; Long GV; McArthur G; Scherag A; Sucker A; Schadendorf D
J Clin Oncol; 2012 Jul; 30(19):2375-83. PubMed ID: 22614973
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
34. A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases.
Zalaudek I; Ciarrocchi A; Piana S; Argenziano G; Torricelli F; Sancisi V; Gandolfi G; Longo C; Moscarella E; Banzi C; Nicoli D
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):387-390. PubMed ID: 24393566
[TBL] [Abstract][Full Text] [Related]
35. Concordance of somatic mutational profile in multiple primary melanomas.
Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
[TBL] [Abstract][Full Text] [Related]
36. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.
Si L; Kong Y; Xu X; Flaherty KT; Sheng X; Cui C; Chi Z; Li S; Mao L; Guo J
Eur J Cancer; 2012 Jan; 48(1):94-100. PubMed ID: 21788131
[TBL] [Abstract][Full Text] [Related]
38. Mind your head: two cases of mucosal metastasis of BRAF-mutated melanoma of the scalp.
Koppes SA; Schrader AMR; Jansen AML; Rijken JA; Kamphuis AM; Blokx WAM
Virchows Arch; 2022 Mar; 480(3):693-697. PubMed ID: 34142226
[TBL] [Abstract][Full Text] [Related]
39. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
40. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]